Table 5.
Infection indication | Iron | Control | Iron per 50 visits n = 26,473 |
Control per 50 visits n = 27,633 |
Incidence ratioa
(95% CI) |
P value | PFDRb |
---|---|---|---|---|---|---|---|
Malariac | 41 | 28 | 0.077 | 0.051 | 1.53 (0.94–2.47) | 0.084 | 0.278 |
Respiratory | 75 | 87 | 0.142 | 0.157 | 0.90 (0.66–1.23) | 0.503 | 0.719 |
Locald | 75 | 57 | 0.142 | 0.103 | 1.37 (0.97–1.94) | 0.071 | 0.278 |
Gastrointestinale | 62 | 30 | 0.117 | 0.054 | 2.16 (1.39–3.34) | <0.001 | 0.005 |
Urinary tractf | 10 | 9 | 0.019 | 0.016 | 1.16 (0.47–2.86) | 0.747 | 0.934 |
STIg | 13 | 7 | 0.025 | 0.013 | 1.94 (0.77–4.86) | 0.158 | 0.292 |
Genitalh | 15 | 16 | 0.028 | 0.029 | 0.98 (0.48–1.98) | 0.952 | 0.993 |
Dental | 11 | 5 | 0.021 | 0.009 | 2.30 (0.80–6.62) | 0.123 | 0.292 |
Meningitis | 0 | 3 | 0 | 0.005 | 0 (NA) | 0.993 | 0.993 |
Miscellaneousi | 29 | 42 | 0.055 | 0.076 | 0.72 (0.45–1.16) | 0.175 | 0.292 |
aIncidence ratio was computed using Poisson regression with the number of visits as the exposure period
b P value adjusted for multiple testing using false discovery rate method [26]
cAntibiotics in addition to anti-malarial treatment
dNon-enteric and non-respiratory, includes ear, skin, ophthalmic, abscess, wounds, local trauma, sinusitis, mastoiditis, keloid, scalp ringworm
eDysentry, typhoid, enteritis, intestinal parasitosis, gastric ulcer, gastroenteritis, diarrhoea and abdominal pain, vomiting and abdominal pain, amoebiasis, colopathy, sub-occlusion
fCystitis, dysuria
gIncludes syphilis, trichomoniasis
hUpper or lower genital infection
iItching, colic, headache, generalised or localised pain, fever, vomiting only, anaemia, anxiety, neuralgia, spasms, urticarial, plus non-infectious specific diagnoses: cancers, fertility problems, angina, self-medication, allergy, burns, renal stones, contraception, thyroid and cardiac diseases, epilepsy, filariasis, foreign body, venomous bites, fractures, migraine, HIV, varicella, mumps, prophylactic and non-classifiable: includes three uncertain descriptors, or absent statement
PFDR positive false discovery rate, STI sexually transmitted infection